CRSP
What one share of Crispr Therapeutics Ag holds
Biological Products, (No Diagnostic Substances)
Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology.
Crispr Therapeutics Ag’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.14 |
|---|---|
| Profit | −$4.76 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$3.92 |
| Cash and investments | $24.46 |
| Debt | $6.06 |
| Book value | $18.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$5.06 | $0.23 | $11.57 | — | −$5.26 |
| 2016 | — | −$1.89 | $0.25 | −$4.56 | — | — |
| 2017 | — | −$1.71 | $0.20 | −$1.94 | — | $4.63 |
| 2018 | — | −$3.44 | $0.06 | −$2.06 | — | $7.56 |
| 2019 | — | $1.17 | $0.12 | $0.88 | — | $15.46 |
| 2020 | — | −$5.29 | $0.28 | −$3.89 | — | $22.52 |
| 2021 | — | $4.70 | $1.02 | $5.69 | — | $31.17 |
| 2022 | — | −$8.36 | $0.48 | −$6.85 | — | $23.89 |
| 2023 | $4.69 | −$1.94 | $0.12 | −$3.41 | — | $23.52 |
| 2024 | $0.44 | −$4.34 | $0.02 | −$1.72 | — | $22.53 |
| 2025 | $0.04 | −$6.47 | $0.01 | −$3.85 | — | $20.04 |